Cargando…
Discontinuation of Peritoneal Dialysis after Late Initiation of Eculizumab in a Case of Familial Atypical Hemolytic-Uremic Syndrome: A Case Report
BACKGROUND: Atypical hemolytic-uremic syndrome is caused by a thrombotic microangiopathy and manifests itself with hemolytic anemia, thrombocytopenia, and organ ischemia. Its etiology is a mutation affecting the genes encoding for proteins of the complement system. Early treatment with eculizumab (8...
Autores principales: | Alonso Valente, Rafael, García Rodríguez, Giannina Elena, García Marcote, Yanina, Fidalgo Díaz, Manuel, Becerra Mosquera, Vanesa, Novoa García, Daniel, Cordal Martínez, Teresa, Díaz Rodríguez, Cándido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465702/ https://www.ncbi.nlm.nih.gov/pubmed/28612003 http://dx.doi.org/10.1159/000457950 |
Ejemplares similares
-
Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?
por: Rodriguez, Eva, et al.
Publicado: (2017) -
A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome
por: AlZabali, Saeed, et al.
Publicado: (2022) -
A Case of Atypical Hemolytic Uremic Syndrome Successfully Treated with Eculizumab
por: Thajudeen, B., et al.
Publicado: (2013) -
Critical appraisal of eculizumab for atypical hemolytic uremic syndrome
por: Palma, Lilian M Pereira, et al.
Publicado: (2016) -
Atypical hemolytic uremic syndrome and eculizumab therapy in children
por: Kim, Seong Heon, et al.
Publicado: (2018)